Heart failure & cardiomyopathies
Association Between Haemoglobin, Albumin, Lymphocytes, and Platelets and Mortality in Patients with Heart Failure
Authors' conclusion
HALP may be a potential marker for predicting mortality in patients with heart failure.
Study context
- Population
- Adults hospitalised with HF, 2019–2021
- Participants
- 730 adults
- Exposure
- Haemoglobin, albumin, lymphocytes, and platelets (HALP) score and mortality
- Outcome
- 1-month mortality and 1-year mortality
- Follow-up
- 1 month and 1 year
Main finding
As reported in the abstract
High HALP scoresOdds ratio (95% CI)P value
1-month mortality
0.978(0.963–0.992)
P = 0.0031-year mortality
0.987(0.977–0.997)
P = 0.009- Died within 1 month
- 61 (8.36%)
- Died within 1 year
- 77 (10.55%)
Observational data: associations, not effects.
Further findings
1-year mortality, by NYHA stage and left ventricular ejection fraction (LVEF) (subgroups)
| OR (95% CI) | P value | ||
|---|---|---|---|
| High HALP scoresNYHA stage II/III | 0.978 (0.957–1.000) | P = 0.045 | |
| High HALP scoresLVEF ≥50% | 0.970 (0.945–0.996) | P = 0.024 | |
| 0.512Odds ratio (log scale) |
AUC
HALP
0.677(95% CI: 0.619-0.735)
PNI
0.666(95% CI: 0.608-0.723)
CRP
0.638(95% CI: 0.572-0.704)
MAGGIC-HF
0.654(95% CI: 0.591-0.717)
Original publication
Association Between Haemoglobin, Albumin, Lymphocytes, and Platelets and Mortality in Patients with Heart Failure. ESC Heart Fail. Published 19 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →